Bausch + Lomb Corporation
Financials
Valuation Metrics
Bausch + Lomb Corporation's Market Cap is $7.13B. At end of 2025 it was $6.04B. Ranked #1087 of 3,115 in US market (top 35%), #735 of 1,643 on NYSE (top 45%), #77 of 203 in Health Care Equipment & Services (top 38%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $7.13B | US#1,087/3,115 Sec#77/203 |
| Revenue | $5.41B | US#844/3,115 Sec#50/203 |
| Net Income | $-111M | US—/3,115 Sec—/203 |
| Total Assets | $13.96B | US#804/3,115 Sec#39/203 |
| Net Assets | $6.44B | US#589/3,115 Sec#35/203 |
| Employees | 13,000 | US#743/3,115 Sec#57/203 |
| Value | ||
| P/B | 1.11x | US#552/3,115 Sec#22/203 |
| P/S | 1.32x | US#955/3,115 Sec#64/203 |
| EV/EBITDA | 9.72x | US#1,640/3,115 Sec#64/203 |
| FCF Yield | 3.56% | US#2,036/3,115 Sec#121/203 |
| Profitability | ||
| ROE | -1.72% | US#2,193/3,115 Sec#118/203 |
| ROA | -0.80% | US#2,323/3,115 Sec#126/203 |
| Op. Margin | 8.41% | US#1,805/3,115 Sec#96/203 |
| Revenue Growth | 8.78% | US#1,363/3,115 Sec#94/203 |
| Financial Health | ||
| Debt Ratio | 115.69% | US#1,232/3,115 Sec#118/203 |
| Total Debt | $45M | US#668/3,115 Sec#34/203 |
| FCF | $254M | US#1,575/3,115 Sec#94/203 |
| Cash | $513M | US#1,266/3,115 Sec#73/203 |
| Current Ratio | 1.56x | US#1,618/3,115 Sec#144/203 |
| Net Debt/EBITDA | -0.68x | US#2,185/3,115 Sec#131/203 |
| Performance | ||
| 1Y Return | 33.90% | US#756/3,115 Sec#68/203 |
| 1M Return | 16.92% | US#177/3,115 Sec#21/203 |
| From 52W High | -6.34% | US#14/3,115 Sec#2/203 |
| 1Y MDD | -20.11% | US#644/3,115 Sec#17/203 |
| Trading | ||
| Volume | 1,285,212 shares | US#495/3,115 Sec#23/203 |
| Trading Value | $26M | US#1,006/3,115 Sec#71/203 |
| Per Share | ||
| EPS | $-0.31 | US—/3,115 Sec—/203 |
| BPS | $18.06 | US#1,351/3,115 Sec#77/203 |
Company Info
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.